Table 3. Linear regression analysis for better glycemic response to SGLT2 inhibitors.

Variable	Univariate		Multivariatea
	β	P value	β	P value
Baseline HbA1c <7% (n=174)
Age, yr	0.001	0.874	0.006	0.268
Female sex	0.089	0.387	0.103	0.319
Initial BMI, kg/m2	−0.033	0.010	−0.031	0.018
DM duration, yr	−0.040	0.001	−0.050	<0.001
Duration of SGLT2 inhibitor use, day	−0.001	0.023	−0.001	0.096
Baseline HbA1c, %	0.316	0.043	0.423	0.005
Total cholesterol, mg/dL	0.002	0.305	0.001	0.588
eGFR, mL/min/1.73 m2	0.005	0.028	0.006	0.012
Metformin use	−0.200	0.292	0.095	0.606
SU use	−0.074	0.586	0.116	0.392
DPP4 inhibitor use	−0.156	0.267	−0.203	0.128
TZD use	−0.184	0.386	0.066	0.749
Baseline HbA1c ≥7% (n=630)
Age, yr	−0.013	0.006	0.007	0.121
Female sex	−0.129	0.195	−0.129	0.136
Initial BMI, kg/m2	0.027	0.019	0.020	0.042
DM duration, yr	−0.028	<0.001	−0.030	<0.001
Duration of SGLT2 inhibitor use, day	0.001	0.638	−0.001	0.847
Baseline HbA1c, %	0.566	<0.001	0.596	<0.001
Total cholesterol, mg/dL	0.003	0.056	0.001	0.949
eGFR, mL/min/1.73 m2	0.008	<0.001	0.007	<0.001
Metformin use	−0.158	0.546	−0.015	0.948
SU use	−0.007	0.943	−0.191	0.034
DPP4 inhibitor use	0.122	0.255	0.229	0.013
TZD use	0.073	0.714	0.093	0.587

SGLT2, sodium-glucose co-transporter 2; HbA1c, glycosylated hemoglobin; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; SU, sulfonylurea; DPP4, dipeptidyl peptidase 4; TZD, thiazolidinedione.

^aAdjusted for age, sex, initial BMI, diabetes duration, duration of SGLT2 inhibitor use, baseline HbA1c and eGFR levels, and anti-diabetic agent use (metformin, SU, DPP4 inhibitor, and TZD).